Background: Docetaxel has shown some activity in advanced gastric cancer. Recent phase I studies found low hematologic toxicity and a favourable toxicity profile when docetaxel was administered on a weekly schedule. In this study, we explored the activity of weekly docetaxel in patients with advanced gastric cancer who failed first-line chemotherapy.
Introduction
In advanced gastric cancer, recent combination chemotherapy regimens have produced high response rates with promising survival times [1, 2] . Unfortunately, about half of the patients receiving chemotherapy are unresponsive and treatment results of second-line chemotherapy are unsatisfactory [3] . Salvage chemotherapy is often burdened by pronounced side-effects and response rates rarely exceed 20%. For these reasons, there is urgent need for novel, active, and less toxic compounds.
Docetaxel has shown single-agent activity in advanced gastric cancer. At doses of 60 to 100 mg/m 2 every three weeks, docetaxel yelded 20% to 24% response rates in chemotherapy-naive and treated patients [4] [5] [6] . In these studies haematologic toxicity was often relevant, and more than half of the patients experienced grade III-IV leucopenia. Mild to moderate non-haematologic toxicities as nausea, vomiting, diarrhoea, asthenia and dermatitis occurred in 40%-50% of the patients.
Recently, the weekly administration of docetaxel has been explored in phase I studies [7] [8] [9] . Hainsworth et al. [7] , reported low incidence of myelosuppression, while asthenia was frequent and dose-limiting toxicity. In minimally pretreated patients, Briasoulis et al. [9] confirmed that protracted weekly administration of docetaxel is feasible, with negligible hematologic toxicity.
On these bases we studied the activity of weekly docetaxel in patients with advanced gastric cancer who failed first-line chemotherapy.
Materials and methods
Patients with relapsed or metastatic gastric cancer with stable or progressing disease after first-line chemotherapy were considered eligible for this study. Other eligibility criteria included: pathologically confirmed gastric cancer, measurable disease, Karnofsky Performance Status (ICPS) equal or >70, age <75 years, normal liver, renal, and bone marrow functions. Written informed consent was obtained from all participants after the nature of the study had been fully explained.
Baseline studies included blood chemistries, urinoanalysis and ECG. Chest X-rays, abdominal ultrasound or computed tomography and any other test to identify the extent of disease was performed. One course of chemotherapy consisted of a weekly administration of docetaxel 36 mg/m 2 as 1-hour intravenous infusion, for six consecutive weeks, followed by a two-weeks rest [7] , All patients received an abbreviated premedication with dexamethasone 8 mg i.m. 12 hours and 1 hour before docetaxel, and again 12 hours following docetaxel administration [7] . Patients were re-evaluated after one course and six more weekly administrations of docetaxel were planned in cases of response or stable disease. All patients had physical examination and blood chemistries before each weekly administration of chemotherapy. Full doses of the anticancer drug were given if leukocyte count was 2,000/ul and platelet count greater than 75,000/ul; when leukocyte and platelet counts were less than these values, treatment was delayed a week or until complete recovery. Docetaxel was restarted at a 75% dose level in case of WHO grade III or IV toxicity with the exception of alopecia and nausea/vomiting.
Response rate and toxicity were the primary endpoints. Objective responses and side-effects were evaluated and graduated according to the standard WHO criteria [10] . According to the optimal two-stage design, for a target activity level of at least 20% response rate, 2 objective responses should be observed in the first 21 evaluable patients (<x and p error probabilities 0.05 and 0.010 respectively).
Results
From January 1999 to October 1999, 21 patients entered on this study. All the patients are evaluable for response and toxicity and their characteristics are reported in Table 1 . The outcome after first-line chemotherapy was disease progression in 11 patients and stable disease in 10 patients. Nine patients had received eight weekly administrations of the PELF regimen [1] . The remaining 12 patients were treated with biweekly fluorouracilcisplatin-folinic acid chemotherapy (8 cycles in 7 patients and 12 cycles in 5 patients).
Salvage chemotherapy with docetaxel was started within six weeks after withdrawal of first-line chemotherapy and at the time of study entry there was a median 3 kg weight loss over the last three months. One patients completed two cycles of chemotherapy, 18 patients received one cycle, and two patients had an abbreviated course with four weeks of docetaxel due to early progression. On the whole, a total of 124 weekly administrations of docetaxel were delivered.
One patient showed partial response, eight patients had stable disease and twelve patients progressed. Patients with stable disease did not receive a second course of weekly docetaxel. Three of them refused and five had persistent asthenia after eight weeks which prompted us to discontinue chemotherapy. At maximum follow-up of 18 months, 1 patient is alive with tumor progression. Median overall survival from the diagnosis of relapsed/ metastatic disease was 7.5 months. Median overall survival from the onset of salvage chemotherapy was 3.5 months.
WHO toxicities in the 21 patients are listed in Table 2 . None of the patients experienced grade IV toxicity. Grade III side-effects occurred in two patients; one patient experienced leukopenia, and one patient suffered from leukopenia, thrombocytopenia and dermatitis. In both cases, a 14-days treatment delay, and a 25% dose reduction in the last three adminstrations were complied. Beginning from the third or the fourth week of chemotherapy, 19 patients (90%) showed grade II asthenia and it resulted the commonest side-effect. Asthenia did not cause any treatment delay or dose reduction, but only three patients fully recovered after eight weeks. Neither fluid retention syndrome nor hypersensitivity reactions were seen using this schedule of docetaxel even with our modified corticosteroid medication.
Discussion
The results of this study showed that weekly docetaxel does not possess significant antitumor activity as salvage chemotherapy in patients with advanced gastric cancer. This schedule did not cause severe hematologic toxicity, but it determined sustained asthenia in most of the patients.
This study was powered to detect a 20% response rate at least, and it is possible that we are missing a true response rate of 5%-15%. However, response rates lesser than 20% would not be considered of great interest, since other schedules of docetaxel and other agents may offer more interesting results. Second-line chemotherapy with docetaxel at a dose of 60-100 mg/m 2 [5, 6] , or paclitaxel in progressing patients after PELF chemo-therapy [11] yelded 20% to 24% response rates. Weekly high-dose fluorouracil and folinic acid achieved 18% reponse rate with a median survival time of 5 months from the onset of salvage chemotherapy [12] . Continuous infusion with mitomycin-C produced one complete and five partial responses in 20 pretreated patients with manageable toxicity [13] . Also, new drugs as irinotecan and uracil-tegafur (UFT) showed promising results in advanced gastric cancer. In early phase II studies emerged potential activity in pretreated patients and their role as salvage chemotherapy is under investigation [14, 15] .
In our experience, asthenia was the commonest sideeffect and its persistence after eight weeks caused the withdrawal of treatment in five patients with stable disease. At baseline evaluation, all of our patients had initial disease-related symptoms as anorexia and asthenia, and a median KPS of 80. It is possible that these characteristics have reduced the treatment compliance to weekly docetaxel. Unlikely, a different population of patients might have yelded a better outcome; patients with advanced gastric cancer with unresponsive disease after first-line chemotherapy usually complain diseaserelated symptoms. Furthermore, data from previous experiences with docetaxel in advanced gastric cancer showed that responses may occur early and independently from the baseline performance status [4] . Concerning toxicity, our findings parallel the results of the phase I studies. Hainsworth et al. [7] found a low incidence of hematologic toxicity, while asthenia resulted the commonest side-effect. Most of their patients received only one course, and it is possible that some cumulative toxicities were underestimated. In our experience also, it was not possible to evaluate properly the cumulative toxicity of prolonged weekly docetaxel. However, cumulative toxicity does not seem relevant; Briasoulis et al. [9] , described mild alopecia, dacryorrhea, fluid retention and asthenia after prolonged use of weekly docetaxel.
It is difficult to explain the particular toxicity profile of weekly docetaxel; one reason could be the variable plasma clearance of the drug depending on doses. Docetaxel pharmacokinetic model was described as biphasic up to 70 mg/m 2 and triphasic at higher doses [16] . When administered in 1-2 hours infusion at 100 mg/m 2 a terminal y half-life of 11 hours is usually detectable.
In our study, we employed an abbreviated corticosteroid premedication like the one used by Hainsworth et al. [7] . Available data suggest that a short duration of corticosteroids is effective to prevent docetaxel-induced fluid retention. Schedules of dexamethasone 8 mg b.i.d for three days and five days resulted equally effective in preventig fluid retention after repeated corses of 100 mg/m 2 docetaxel [15] . Also, the results reported by Briasoulis et al. [9] support evidence that treatment with weekly docetaxel does not require protracted use of corticosteroids.
To the best of our knowledge, we have reported the first experience of weekly docetaxel in advanced gastric cancer. Though the unsatisfactory results, this drug and schedule deserve further investigation in the overall treatment of the disease. Untreated patients who received docetaxel-cisplatin every three weeks yelded 56% response rate [18] . The same combination plus fluorouracil showed similar activity [19] . In both experiences grade III-IV hematologic toxicity was relevant and the addiction of fluorouracil increased the incidence of stomatitis. In the setting of first-line chemotherapy, multi-drug regimens including weekly docetaxel might be effective and less toxic.
